(Q34236658)

31 July 2017

1 reference

title

Monoclonal antibody therapy. (English)

1 reference

31 July 2017

1 reference

Park JW

1

1 reference

31 July 2017

Smolen J

series ordinal

2

1 reference

31 July 2017

publication date

1 January 2001

1 reference

Advances in Protein Chemistry

31 July 2017

published in

1 reference

31 July 2017

volume

56

1 reference

31 July 2017

page(s)

369-421

1 reference

MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation

31 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Somatic generation of antibody diversity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Gene rearrangement and B-cell development

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Mutation drift and repertoire shift in the maturation of the immune response

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Structural basis of antibody function

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Some important issues in the planning of phase III HIV vaccine efficacy trials

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Global immunization for the 21st century

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Continuous cultures of fused cells secreting antibody of predefined specificity

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Transfectomas provide novel chimeric antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

"Primatization" of recombinant antibodies for immunotherapy of human diseases: a macaque/human chimeric antibody against human CD4

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Reshaping human antibodies for therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Comparison of strategies for the construction of libraries of artificial antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

1 reference

7 January 2021

Production of antigen-specific human antibodies from mice engineered with human heavy and light chain YACs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Isolation of recombinant proteins from milk

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Properties of purified T cell subsets. II. In vivo responses to class I vs. class II H-2 differences

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

The differentiation and function of human T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

The T cell receptor as a multicomponent signalling machine: CD4/CD8 coreceptors and CD45 in T cell activation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

OKT3 treatment of steroid-resistant renal allograft rejection.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

The use of antibodies against the IL-2 receptor in transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipients. CHIB 201 International Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Patterns of graft infiltration and cytokine gene expression during the first 10 days of kidney transplantation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Immunoprophylaxis with a monoclonal anti-IL-2 receptor antibody in liver transplant patients

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Molecular mechanisms of platelet aggregation

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Integrin-ligand interactions: a year in review

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Toward a new frontier in myocardial reperfusion therapy: emerging platelet preeminence

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Platelets and thrombolytic therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

A new murine monoclonal antibody reports an activation-dependent change in the conformation and/or microenvironment of the platelet glycoprotein IIb/IIIa complex

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

A monoclonal antibody against the platelet glycoprotein IIb/IIIa receptor complex prevents platelet aggregation and thrombosis in a canine model of coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Safety and antiplatelet effect of murine monoclonal antibody 7E3 Fab directed against platelet glycoprotein IIb/IIIa in patients undergoing elective coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high-risk coronary angioplasty.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Randomised trial of coronary intervention with antibody against platelet IIb/IIIa iritegrin for reduction of clinical restenosis: results at six months

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Complementary Clinical Benefits of Coronary-Artery Stenting and Blockade of Platelet Glycoprotein IIb/IIIa Receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels. c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Platelet GPIIb-IIIa blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Beta3 integrins are upregulated after vascular injury and modulate thrombospondin- and thrombin-induced proliferation of cultured smooth muscle cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

THE ROLE OF CYTOKINES IN THE FAILING HUMAN HEART

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Natural variability of circulating levels of cytokines and cytokine receptors in patients with heart failure: implications for clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Tissue expression and immunolocalization of tumor necrosis factor-alpha in postinfarction dysfunctional myocardium

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

The pathogenesis of sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Septic shock in humans. Advances in the understanding of pathogenesis, cardiovascular dysfunction, and therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Tumor necrosis factor in the pathophysiology of infection and sepsis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Mice deficient for the 55 kd tumor necrosis factor receptor are resistant to endotoxic shock, yet succumb to L. monocytogenes infection

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. The CB0006 Sepsis Syndrome Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Assessment of the safety and efficacy of the monoclonal anti-tumor necrosis factor antibody-fragment, MAK 195F, in patients with sepsis and septic shock: a multicenter, randomized, placebo-controlled, dose-ranging study.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Efficacy and safety of monoclonal antibody to human tumor necrosis factor alpha in patients with sepsis syndrome. A randomized, controlled, double-blind, multicenter clinical trial. TNF-alpha MAb Sepsis Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Monoclonal antibody to TNF in severe septic shock

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Administration of anti-TNF antibody improves left ventricular function in septic shock patients. Results of a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Group A streptococcal bacteremia: the role of tumor necrosis factor in shock and organ failure

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Treatment of septic shock with the tumor necrosis factor receptor:Fc fusion protein. The Soluble TNF Receptor Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Treatment of gram-negative bacteremia and shock with human antiserum to a mutant Escherichia coli

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Treatment of severe infectious purpura in children with human plasma from donors immunized with Escherichia coli J5: a prospective double-blind study. J5 study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Treatment of septic shock with human monoclonal antibody HA-1A. A randomized, double-blind, placebo-controlled trial. CHESS Trial Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Randomized, placebo-controlled trial of HA-1A, a human monoclonal antibody to endotoxin, in children with meningococcal septic shock. European Pediatric Meningococcal Septic Shock Trial Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Assessment of the effect of candidate anti-inflammatory treatments on the interaction between meningococci and inflammatory cells in vitro in a whole blood model

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Reduction of respiratory syncytial virus (RSV) in tracheal aspirates in intubated infants by use of humanized monoclonal antibody to RSV F protein

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Pannus and pannocytes. Alternative models of joint destruction in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Inhibition of the production and effects of interleukin-1 and tumor necrosis factor alpha in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Inhibitory effect of TNF alpha antibodies on synovial cell interleukin-1 production in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Cytokine production by synovial T cells in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Monoclonal anti‐TNFα Antibody as a Probe of Pathogenesis and Therapy of Rheumatoid Disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor alpha (cA2) versus placebo in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Repeated therapy with monoclonal antibody to tumour necrosis factor alpha (cA2) in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Deactivation of vascular endothelium by monoclonal anti-tumor necrosis factor alpha antibody in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Decrease in cellularity and expression of adhesion molecules by anti-tumor necrosis factor alpha monoclonal antibody treatment in patients with rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Neutralization of TNF by the antibody cA2 reveals differential regulation of adhesion molecule expression on TNF-activated endothelial cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Chimeric anti-TNF-alpha monoclonal antibody cA2 binds recombinant transmembrane TNF-alpha and activates immune effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Tumour necrosis factor alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

1 reference

7 January 2021

Building towards a consensus for the use of tumour necrosis factor blocking agents

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Preferential localization of systemically administered radiolabeled interleukin 1alpha in experimental inflammation in mice by binding to the type II receptor.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Joint inflammation and cartilage destruction may occur uncoupled

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Blockage of interleukin-6 receptor ameliorates joint disease in murine collagen-induced arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

The importance of the T cell in initiating and maintaining the chronic synovitis of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Humanised monoclonal antibody therapy for rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

CAMPATH-1H, a humanized monoclonal antibody, in refractory rheumatoid arthritis. An intravenous dose-escalation study

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Treatment of rheumatoid arthritis with an anti-CD4 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Reduction of synovial inflammation after anti-CD4 monoclonal antibody treatment in early rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Humanized anti-CD4 monoclonal antibody therapy of autoimmune and inflammatory disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Successful treatment of autoimmunity in NZB/NZW F1 mice with monoclonal antibody to L3T4.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Treatment of severe systemic lupus erythematosus with anti-CD4 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

In vivo CD40-gp39 interactions are essential for thymus-dependent humoral immunity. I. In vivo expression of CD40 ligand, cytokines, and antibody production delineates sites of cognate T-B cell interactions

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Activation of human dendritic cells through CD40 cross-linking.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

In the absence of a CD40 signal, B cells are tolerogenic.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Prevention of collagen-induced arthritis with an antibody to gp39, the ligand for CD40

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Antibody to the ligand of CD40, gp39, blocks the occurrence of the acute and chronic forms of graft-vs-host disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Tumour-necrosis-factor antibody treatment in Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Infliximab for the treatment of fistulas in patients with Crohn's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Phage libraries--a new route to clinically useful antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Treatment of B-Cell Lymphoma with Monoclonal Anti-Idiotype Antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

CD20: a regulator of cell-cycle progression of B lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Molecular cloning of the human B cell CD20 receptor predicts a hydrophobic protein with multiple transmembrane domains

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Radioimmunotherapy of B-cell lymphoma with [131I]anti-B1 (anti-CD20) antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Iodine-131-anti-B1 radioimmunotherapy for B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Radiolabeled-antibody therapy of B-cell lymphoma with autologous bone marrow support

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Phase II trial of 131I-B1 (anti-CD20) antibody therapy with autologous stem cell transplantation for relapsed B cell lymphomas.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Follow-up of relapsed B-cell lymphoma patients treated with iodine-131-labeled anti-CD20 antibody and autologous stem-cell rescue

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Initial experience with treatment of human B cell lymphoma with anti-CD19 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Anti-B4-blocked ricin: a phase I trial of 7-day continuous infusion in patients with B-cell neoplasms.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Complete regression of human B-cell lymphoma xenografts in mice treated with recombinant anti-CD22 immunotoxin RFB4(dsFv)-PE38 at doses tolerated by cynomolgus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Targeting, dosimetry, and radioimmunotherapy of B-cell lymphomas with iodine-131-labeled LL2 monoclonal antibody

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

The CAMPATH-1 antigen (CDw52)

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Humanized CD52 monoclonal antibody campath-1H as first-line treatment in chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

In vivo 'Purging' of residual disease in CLL with Campath-1H

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Transforming genes of carcinomas and neuroblastomas introduced into mouse fibroblasts

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Amplification of a novel v-erbB-related gene in a human mammary carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

The neu gene: an erbB-homologous gene distinct from and unlinked to the gene encoding the EGF receptor

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Localization of a novel v-erbB-related gene, c-erbB-2, on human chromosome 17 and its amplification in a gastric cancer cell line

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Early and multifocal tumors in breast, salivary, Harderian and epididymal tissues developed in MMTY-Neu transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Stochastic appearance of mammary tumors in transgenic mice carrying the MMTV/c-neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Biological effects of monoclonal antireceptor antibodies reactive with neu oncogene product, p185neu

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

A subclass of tumor-inhibitory monoclonal antibodies to ErbB-2/HER2 blocks crosstalk with growth factor receptors

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Regulation of cellular response to cisplatin-induced DNA damage and DNA repair in cells overexpressing p185(erbB-2) is dependent on the ras signaling pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Should we treat HER, too?

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Oncogene alterations in endometrial carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

HER-2/neu expression in pancreatic adenocarcinoma: relation to tumor differentiation and survival

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Amplification and expression of the c-erb B-2/neu proto-oncogene in human bladder cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Expression of c-erbB-2 protein product in bladder cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Overexpression of her-2/neu in human prostate cancer and benign hyperplasia

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Prognostic significance of HER-2/neu gene amplification status by fluorescence in situ hybridization of prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Stability of HER-2/neu expression over time and at multiple metastatic sites

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Differential responses of human tumor cell lines to anti-p185HER2 monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Identification of heregulin, a specific activator of p185erbB2

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Isolation of the neu/HER-2 stimulatory ligand: a 44 kd glycoprotein that induces differentiation of mammary tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Comparison of fluorescence in situ hybridization and immunohistochemistry for the evaluation of HER-2/neu in breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Sterically stabilized anti-HER2 immunoliposomes: design and targeting to human breast cancer cells in vitro.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Anti-HER2 immunoliposomes for targeted therapy of human tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Presence of epidermal growth factor receptor as an indicator of poor prognosis in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Epidermal growth factor receptors in non-small cell lung cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Epidermal-growth-factor receptors in human bladder cancer: comparison of invasive and superficial tumours

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Deletion-mutant epidermal growth factor receptor in human gliomas: Effect of type II mutation on receptor function

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Antitumor effects of doxorubicin in combination with anti-epidermal growth factor receptor monoclonal antibodies

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

Tumor necrosis factor-alpha and the failing human heart

1 reference

https://api.crossref.org/works/10.1016%2FS0065-3233%2801%2956010-6

7 January 2021

10.1016/S0065-3233(01)56010-6

Identifiers

DOI

1 reference

31 July 2017

1 reference